BACKGROUND: Our recent work demonstrated that treatment of neuroblastoma with triptolide causes apoptotic cell death in vitro and decreases tumor size in vivo. Triptolide therapy has been associated with reduced expression of Hsp-70, suggesting a mechanism of cell killing involving Hsp-70 inhibition. The principal objective of this study was to investigate the role of Hsp-70 in triptolide-mediated cell death in neuroblastoma. MATERIALS AND METHODS: Neuroblastoma cells were transfected with Hsp-70-specific siRNA. Viability, caspase activity, and phosphatidylserine externalization were subsequently measured. An orthotopic, syngeneic murine tumor model was developed, and randomized mice received daily injections of triptolide or vehicle. At 21 d, mice were sacrificed. Immunohistochemisty was used to characterize Hsp-70 levels in residual tumors, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed to identify cells undergoing apoptosis. RESULTS: Targeted silencing of Hsp-70 with siRNA significantly decreased cellular viability, augmented caspase-3 activity, and resulted in increased annexin-V staining. These effects parallel those findings obtained following treatment with triptolide. Residual tumors from triptolide-treated mice showed minimal staining with Hsp-70 immunohistochemistry, while control tumors stained prominently. Tumors from treated mice demonstrated marked staining with the TUNEL assay, while control tumors showed no evidence of apoptosis. CONCLUSIONS: Use of siRNA to suppress Hsp-70 expression in neuroblastoma resulted in apoptotic cell death, similar to the effects of triptolide. Residual tumors from triptolide-treated mice expressed decreased levels of Hsp-70 and demonstrated significant apoptosis. These findings support the hypothesis that Hsp-70 inhibition plays a significant role in triptolide-mediated neuroblastoma cell death. Copyright 2010 Elsevier Inc. All rights reserved.
BACKGROUND: Our recent work demonstrated that treatment of neuroblastoma with triptolide causes apoptotic cell death in vitro and decreases tumor size in vivo. Triptolide therapy has been associated with reduced expression of Hsp-70, suggesting a mechanism of cell killing involving Hsp-70 inhibition. The principal objective of this study was to investigate the role of Hsp-70 in triptolide-mediated cell death in neuroblastoma. MATERIALS AND METHODS:Neuroblastoma cells were transfected with Hsp-70-specific siRNA. Viability, caspase activity, and phosphatidylserine externalization were subsequently measured. An orthotopic, syngeneic murinetumor model was developed, and randomized mice received daily injections of triptolide or vehicle. At 21 d, mice were sacrificed. Immunohistochemisty was used to characterize Hsp-70 levels in residual tumors, and terminal deoxynucleotidyl transferasedUTP nick end labeling (TUNEL) was performed to identify cells undergoing apoptosis. RESULTS: Targeted silencing of Hsp-70 with siRNA significantly decreased cellular viability, augmented caspase-3 activity, and resulted in increased annexin-V staining. These effects parallel those findings obtained following treatment with triptolide. Residual tumors from triptolide-treated mice showed minimal staining with Hsp-70 immunohistochemistry, while control tumors stained prominently. Tumors from treated mice demonstrated marked staining with the TUNEL assay, while control tumors showed no evidence of apoptosis. CONCLUSIONS: Use of siRNA to suppress Hsp-70 expression in neuroblastoma resulted in apoptotic cell death, similar to the effects of triptolide. Residual tumors from triptolide-treated mice expressed decreased levels of Hsp-70 and demonstrated significant apoptosis. These findings support the hypothesis that Hsp-70 inhibition plays a significant role in triptolide-mediated neuroblastoma cell death. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: T Teitz; T Wei; M B Valentine; E F Vanin; J Grenet; V A Valentine; F G Behm; A T Look; J M Lahti; V J Kidd Journal: Nat Med Date: 2000-05 Impact factor: 53.440
Authors: Mara B Antonoff; Rohit Chugh; Daniel Borja-Cacho; Vikas Dudeja; Kimberly A Clawson; Steven J Skube; Brent S Sorenson; Daniel A Saltzman; Selwyn M Vickers; Ashok K Saluja Journal: Surgery Date: 2009-08 Impact factor: 3.982
Authors: Phoebe A Phillips; Vikas Dudeja; Joshua A McCarroll; Daniel Borja-Cacho; Rajinder K Dawra; William E Grizzle; Selwyn M Vickers; Ashok K Saluja Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith Journal: FEBS J Date: 2015-10-18 Impact factor: 5.542
Authors: Blake A Jacobson; Esther Z Chen; Shaogeng Tang; Holly Sedgwick Belgum; Joel A McCauley; Kristen A Evenson; Ryan G Etchison; Joe Jay-Dixon; Manish R Patel; Ahmad Raza; Ashok K Saluja; Jonathan D'Cunha; Robert A Kratzke Journal: Genes Cancer Date: 2015-03
Authors: Satish Patil; Lev G Lis; Robert J Schumacher; Beverly J Norris; Monique L Morgan; Rebecca A D Cuellar; Bruce R Blazar; Raj Suryanarayanan; Vadim J Gurvich; Gunda I Georg Journal: J Med Chem Date: 2015-11-24 Impact factor: 7.446
Authors: Ilona Rousalova; Sulagna Banerjee; Veena Sangwan; Kristen Evenson; Joel A McCauley; Robert Kratzke; Selwyn M Vickers; Ashok Saluja; Jonathan D'Cunha Journal: PLoS One Date: 2013-10-15 Impact factor: 3.240